$BCTX receives its 4th consecutive positive DSMB recommendation for its Phase 3 study of Bria-IMT™ in metastatic breast cancer, with no safety concerns and the trial continuing without modification, showing confidence in Bria-IMT’s safety profile.

https://globenewswire.com/news-release/2025/1...ancer.html

#BCTX #Biotech #CancerResearch #BreastCancer #Immunotherapy #MedicalInnovation #HealthTech #Oncology #BioInvesting #Pharma